Victor M Rivera

List of Publications by Year in Descending Order

63 papers	6,729 citations	35 h-index	64 g-index
64 ext. papers	7,531 ext. citations	8.2 avg, IF	4.81 L-index

#	Paper	IF	Citations
63	PHASE 2 STUDY OF PONATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS: EFFICACY, SAFETY, AND IMPACT OF LIQUID BIOPSY AND OTHER BIOMARKERS.. *Clinical Cancer Research*, **2022** ,	12.9	4
62	Mobocertinib (TAK-788): A Targeted Inhibitor of Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. *Cancer Discovery*, **2021**, 11, 1672-1687	24.4	34
61	Targeting Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. *Cancer Research*, **2021**, 81, 5311-5324	10.1	7
60	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. *Blood Cancer Journal*, **2020**, 10, 61	7	5
59	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. *Blood*, **2018**, 132, 393-404	2.2	221
58	Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. *Clinical Cancer Research*, **2018**, 24, 5321-5334	12.9	15
57	RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. *Oncotarget*, **2018**, 9, 29654-29664	5.3	45
56	The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. *Blood*, **2016**, 127, 1870-80	21.2	45
55	The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. *Clinical Cancer Research*, **2016**, 22, 5527-5538	12.9	189
54	Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. *Oncotarget*, **2016**, 7, 29011-22	3.3	36
53	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 612-21	21.7	164
52	Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. *Journal of Medicinal Chemistry*, **2016**, 59, 4948-64	8.3	197
51	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. *Blood*, **2016**, 127, 703-12	2.2	65
50	Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. *Oncotarget*, **2015**, 6, 32646-55	3.3	56
49	Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants **2015**,		4
48	Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models **2015**,		6
47	Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. *Clinical Cancer Research*, **2014**, 20, 5745-5755	12.9	113

46	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. *Blood*, **2014**, 124, 3135-3135	2.2	35
45	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. *Blood*, **2014**, 124, 4552-4552	2.2	8
44	Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. *Cancer Chemotherapy and Pharmacology*, **2013**, 71, 1315-23	3.5	53
43	Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants. *Blood*, **2013**, 122, 3992-3992	2.2	8
42	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). *Blood*, **2013**, 122, 652-652	2.2	6
41	Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. *International Journal of Oncology*, **2012**, 41, 425-32	4.4	25
40	Dimerizer-mediated regulation of gene expression in vivo. *Cold Spring Harbor Protocols*, **2012**, 2012, 821-42	1.2	12
39	Ponatinib in refractory Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **2012**, 367, 2075-88	59.2	556
38	Dimerizer-mediated regulation of gene expression in vitro. *Cold Spring Harbor Protocols*, **2012**, 2012, 815-20	1.2	5
37	Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. *Molecular Cancer Therapeutics*, **2012**, 11, 690-9	6.1	255
36	Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. *Cancer Chemotherapy and Pharmacology*, **2012**, 69, 849-60	3.5	15
35	Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. *Cancer Chemotherapy and Pharmacology*, **2012**, 69, 1369-77	3.5	17
34	Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. *Journal of Clinical Oncology*, **2012**, 30, 78-84	2.2	204
33	Dimerizer-mediated regulation of gene expression. *Cold Spring Harbor Protocols*, **2012**, 2012, 767-70	1.2	6
32	Abstract 853: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFR and FGFR1 **2012**,		3
31	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. *Blood*, **2012**, 120, 3747-3747	2.2	6
30	The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. *Blood*, **2011**, 118, 5250-4	2.2	34
29	Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. *Chemical Biology and Drug Design*, **2011**, 77, 1-11	2.9	181

28	Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. *Chemical Biology and Drug Design*, **2011**, 78, 999-1005	2.9	113
27	Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. *Molecular Cancer Therapeutics*, **2011**, 10, 1028-35	6.1	107
26	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 7535-40	11.5	445
25	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3743-8	2.9	12
24	Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. *Molecular Cancer Therapeutics*, **2011** , 10, 1059-71	6.1	81
23	Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands. *Toxicological Sciences*, **2011**, 123, 247-55	4.4	4
22	Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. *Molecular Cancer Therapeutics*, **2011**, 10, 1959-68	6.1	45
21	Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. *Journal of Clinical Oncology*, **2010**, 28, 4554-61	2.2	43
20	Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}ben (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. *Journal of Medicinal Chemistry*, **2010**, 53, 4701-19	8.3	242
19	A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings. *Blood*, **2010**, 116, 210-210	2.2	30
18	A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. *Clinical Cancer Research*, **2009**, 15, 1428-34	12.9	80
17	AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. *Cancer Cell*, **2009**, 16, 401-12	24.3	852
16	A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. *Clinical Cancer Research*, **2008**, 14, 2756-62	12.9	212
15	Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. *Journal of Clinical Oncology*, **2008**, 26, 361-7	2.2	253
14	Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer. *Molecular Therapy*, **2007**, 15, 912-20	11.7	20
13	Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. *Molecular Therapy*, **2006**, 13, 167-74	11.7	22
12	Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. *Human Gene Therapy*, **2005**, 16, 178-86	4.8	110
11	Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. *Blood*, **2005**, 105, 1424-30	2.2	225

10	Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. *Blood*, **2004**, 104, 2532-9	2.2	170
9	Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model. *Molecular Therapy*, **2003**, 7, 493-7	11.7	46
8	Regulation of gene expression by synthetic dimerizers with novel specificity. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 3181-4	2.9	12
7	A system for small-molecule control of conditionally replication-competent adenoviral vectors. *Molecular Therapy*, **2002**, 5, 195-203	11.7	44
6	Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. *Molecular Therapy*, **2002**, 6, 238-42	11.7	84
5	Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. *Science*, **1999**, 283, 88-91	33.3	290
4	Regulation of gene expression with synthetic dimerizers. *Methods in Enzymology*, **1999**, 306, 263-81	1.7	12
3	Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins. *Bioorganic and Medicinal Chemistry*, **1998**, 6, 1309-35	3.4	59
2	Controlling gene expression using synthetic ligands. *Methods*, **1998**, 14, 421-9	4.6	28
1	A humanized system for pharmacologic control of gene expression. *Nature Medicine*, **1996**, 2, 1028-32	50.5	483